{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:58:31Z","timestamp":1791266311382,"version":"4.1.0"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2014,9,15]],"date-time":"2014-09-15T00:00:00Z","timestamp":1410739200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0105919","type":"journal-article","created":{"date-parts":[[2014,9,15]],"date-time":"2014-09-15T13:46:33Z","timestamp":1410788793000},"page":"e105919","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":49,"title":["MET and PI3K\/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma"],"prefix":"10.1371","volume":"9","author":[{"given":"Rajani","family":"Kanteti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Immanuel","family":"Dhanasingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances E.","family":"Lennon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qudsia","family":"Arif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifat","family":"Hasina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya N.","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wickii","family":"Vigneswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanguy","family":"Seiwert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedy L.","family":"Kindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,9,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/ncponc0839","article-title":"Malignant pleural mesothelioma: current concepts in treatment","volume":"4","author":"A Tsiouris","year":"2007","journal-title":"Nat Clin Pract Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/sonc.2002.30237","article-title":"The epidemiology of mesothelioma","volume":"29","author":"M Britton","year":"2002","journal-title":"Semin Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nm0897-913","article-title":"The retinoblastoma gene family pRb\/p105, p107, pRb2\/p130 and simian virus-40 large T-antigen in human mesotheliomas","volume":"3","author":"A De Luca","year":"1997","journal-title":"Nat Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1158\/0008-5472.CAN-05-4642","article-title":"Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey","volume":"66","author":"AU Dogan","year":"2006","journal-title":"Cancer Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.21971","article-title":"The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma","volume":"107","author":"JD Tward","year":"2006","journal-title":"Cancer"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"NJ Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada","volume":"23","author":"JP van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1055\/s-0031-1272874","article-title":"Update on malignant pleural mesothelioma","volume":"32","author":"NP Campbell","year":"2011","journal-title":"Semin Respir Crit Care Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/35077225","article-title":"Oncogenic kinase signalling","volume":"411","author":"P Blume-Jensen","year":"2001","journal-title":"Nature"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/bjc.1990.207","article-title":"Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody","volume":"61","author":"H Dazzi","year":"1990","journal-title":"Br J Cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1158\/0008-5472.CAN-04-1898","article-title":"Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes","volume":"64","author":"CD Hoang","year":"2004","journal-title":"Cancer Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"455S","DOI":"10.1378\/chest.116.suppl_3.455S","article-title":"Emerging translational therapies for mesothelioma","volume":"116","author":"HI Pass","year":"1999","journal-title":"Chest"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/0008-5472.CAN-04-4567","article-title":"Functional analysis of c-Met\/hepatocyte growth factor pathway in malignant pleural mesothelioma","volume":"66","author":"R Jagadeeswaran","year":"2006","journal-title":"Cancer Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/carcin\/bgp097","article-title":"Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells","volume":"30","author":"K Kawaguchi","year":"2009","journal-title":"Carcinogenesis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"9479","DOI":"10.1158\/0008-5472.CAN-08-1643","article-title":"Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations","volume":"68","author":"S Yano","year":"2008","journal-title":"Cancer Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1158\/1535-7163.MCT-09-1173","article-title":"ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity","volume":"9","author":"N Munshi","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11912-012-0227-y","article-title":"PI3K and mTOR signaling pathways in cancer: new data on targeted therapies","volume":"14","author":"L Willems","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1093\/annonc\/mds011","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors","volume":"23","author":"B Markman","year":"2012","journal-title":"Ann Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.yexcr.2008.11.007","article-title":"The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma","volume":"315","author":"P Baumann","year":"2009","journal-title":"Exp Cell Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/sj.bjc.6604995","article-title":"Activity of a novel, dual PI3-kinase\/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts","volume":"100","author":"P Cao","year":"2009","journal-title":"Br J Cancer"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1158\/1078-0432.CCR-09-3022","article-title":"The efficacy of the novel dual PI3-kinase\/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma","volume":"16","author":"DC Cho","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-08-1385","article-title":"NVP-BEZ235, a dual PI3K\/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations","volume":"68","author":"V Serra","year":"2008","journal-title":"Cancer Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1158\/1535-7163.MCT-11-0446","article-title":"GDC-0980 is a novel class I PI3K\/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway","volume":"10","author":"JJ Wallin","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/labinvest.2008.168","article-title":"PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription","volume":"89","author":"R Kanteti","year":"2009","journal-title":"Lab Invest"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1158\/0008-5472.CAN-04-2650","article-title":"Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer","volume":"65","author":"PC Ma","year":"2005","journal-title":"Cancer Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1113\/jphysiol.2009.180331","article-title":"Activation of native TRPC1\/C5\/C6 channels by endothelin-1 is mediated by both PIP3 and PIP2 in rabbit coronary artery myocytes","volume":"587","author":"SN Saleh","year":"2009","journal-title":"J Physiol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"TC Chou","year":"2006","journal-title":"Pharmacol Rev"},{"key":"ref28","first-page":"6272","article-title":"c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions","volume":"63","author":"PC Ma","year":"2003","journal-title":"Cancer Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"9075","DOI":"10.1038\/sj.onc.1207233","article-title":"Microtubule-targeted anticancer agents and apoptosis","volume":"22","author":"KN Bhalla","year":"2003","journal-title":"Oncogene"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1476-4598-6-24","article-title":"The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention","volume":"6","author":"JP Alao","year":"2007","journal-title":"Mol Cancer"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.lungcan.2012.02.022","article-title":"Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM)","volume":"77","author":"S Cedres","year":"2012","journal-title":"Lung Cancer"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1369\/jhc.5A6807.2006","article-title":"Phosphorylated extracellular signal-regulated kinases are significantly increased in malignant mesothelioma","volume":"54","author":"M de Melo","year":"2006","journal-title":"J Histochem Cytochem"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3892\/ijo.2012.1462","article-title":"Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo","volume":"41","author":"S Miyoshi","year":"2012","journal-title":"Int J Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.25555","article-title":"Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma","volume":"117","author":"S Varghese","year":"2011","journal-title":"Cancer"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"20666","DOI":"10.1074\/jbc.M110.213801","article-title":"Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197","volume":"286","author":"S Eathiraj","year":"2011","journal-title":"J Biol Chem"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1158\/1078-0432.CCR-12-3459","article-title":"Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET","volume":"19","author":"C Basilico","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/0008-5472.CAN-12-3256","article-title":"Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition","volume":"73","author":"R Katayama","year":"2013","journal-title":"Cancer Res"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2005.10.016","article-title":"EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations","volume":"51","author":"A Destro","year":"2006","journal-title":"Lung Cancer"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/1471-2407-13-269","article-title":"EphB4 as a therapeutic target in mesothelioma","volume":"13","author":"R Liu","year":"2013","journal-title":"BMC Cancer"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/onc.2010.398","article-title":"Phosphorylation of focal adhesion kinase on tyrosine 194 by Met leads to its activation through relief of autoinhibition","volume":"30","author":"TH Chen","year":"2011","journal-title":"Oncogene"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1158\/0008-5472.CAN-07-1998","article-title":"Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion","volume":"68","author":"R Jagadeeswaran","year":"2008","journal-title":"Cancer Res"},{"key":"ref42","article-title":"miR-137 impairs the proliferative and migratory capacity of human non-small cell lung cancer cells by targeting paxillin","author":"Y Bi","year":"2013","journal-title":"Hum Cell"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/1947601913486348","article-title":"RACK1 Function in Cell Motility and Protein Synthesis","volume":"4","author":"V Gandin","year":"2013","journal-title":"Genes Cancer"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/bcr3039","article-title":"Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer","volume":"13","author":"TW Miller","year":"2011","journal-title":"Breast Cancer Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"S Wullschleger","year":"2006","journal-title":"Cell"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"DA Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"e69104","DOI":"10.1371\/journal.pone.0069104","article-title":"Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells","volume":"8","author":"SJ Fei","year":"2013","journal-title":"PLoS One"},{"key":"ref48","first-page":"849","article-title":"The dual PI3K\/mTOR inhibitor BEZ235 is effective in lung cancer cell lines","volume":"31","author":"VA Herrera","year":"2011","journal-title":"Anticancer Res"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1158\/1535-7163.MCT-09-0160","article-title":"NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas","volume":"8","author":"TJ Liu","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"e25132","DOI":"10.1371\/journal.pone.0025132","article-title":"The dual PI3K\/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer","volume":"6","author":"J Roper","year":"2011","journal-title":"PLoS One"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4161\/cbt.12.6.16397","article-title":"Augmentation of NVP-BEZ235&apos;s anticancer activity against human lung cancer cells by blockage of autophagy","volume":"12","author":"CX Xu","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/JTO.0b013e31820e1a25","article-title":"Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy","volume":"6","author":"MA Hoda","year":"2011","journal-title":"J Thorac Oncol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbrc.2012.12.120","article-title":"Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells","volume":"431","author":"M Humbert","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1177\/1758834011423403","article-title":"In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs","volume":"3","author":"N Sharma","year":"2011","journal-title":"Ther Adv Med Oncol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0105919","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T20:30:38Z","timestamp":1565814638000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0105919"}},"subtitle":[],"editor":[{"given":"Qiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,9,15]]},"references-count":54,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,9,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0105919","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,15]]}}}